THE METHODS REPORTER (Free subscription) | yesterday
Chicago north suburban-based Abbott Laboratories has drawn a flag on the marketing field for its promotion of its bipolar disorder & epilepsy treatment drug--Depakote. Desparate acts in the face... (Like this story? Click the headline to vote it up on WindyCitizen.com)
Pharmalot (Free subscription) | 11/06/2009
As they say: another day, another probe into a drugmaker. The latest - the US Department of Justice is investigating Abbott’s sales and marketing activities of the pill, which is used to treat bipolar disorder, seizures and migraines, according to its quarterly filing with the US Securities and Exchange Commission for Depakote. The government wants [...]
Xconomy (Free subscription) | 11/04/2009
There’s big news about Enlight Biosciences breaking here at the Xconomy Forum: Pharma’s Bet on Boston Innovation. Abbott Laboratories (NYSE:ABT) has joined the consortium of big pharmas that are supporting Enlight, according to CEO David Steinberg; the Boston-based startup is out to develop platform technologies to help large drug companies like Abbott streamline the processes [...]
Furious Seasons (Free subscription) | 11/06/2009
News is out that the federal Department of Justice is investigating Abbott Labs over questions about its marketing of Depakote, its anti-seizure drug that's also approved for bipolar disorder. It's not clear what the scope of the investigation is, so...
Radon Mitigation Pittsburgh (Free subscription) | 11/02/2009
... in the U.S. include a large transportation technology company and a medical equipment division of Abbott Labs. I am really impressed with Martels success in delivering complex custom print solutions. I am keen on bringing these to the North America market where there are strong needs across industries for custom print solutions, said Liz Peirce, Director of North American Business Development,...
Fool.com (Free subscription) | 11/03/2009
... different classes is fairly common. Merck's Vytorin is a combination of its Zetia and Zocor, and Abbott Labs (NYSE: ) and AstraZeneca (NYSE: ) are working on a combination of their TriLipix and Crestor, respectively. But, as far as I know, Merck doesn't have a partnership with Pfizer, and it would probably have to wait until the patents expire in 2011 before selling the combination drug.Then...
eDrugSearch Blog (Free subscription) | 11/03/2009
... the recent trial disappointments.) The next five top sellers, in order, are expected to be Humira (Abbott Labs), Rituxan (Roche), Enbrel (Wyeth/Amgen), Lantus (Sanofi-Aventis), and Herceptin (also Roche). Evaluate also predicts that half of the top 100 drugs in 2014 will be biotech meds — a huge change from last year’s level of 28 percent and 11 percent in 2000. Because biologics are so...
